Mizuho Securities Reiterates Neutral on Sabra Health Care REIT (SBRA) After Meeting with Management
- Top 10 News for 12/2: Crude Rips on OPEC Cut; Starbucks' Schultz Steps Down; Nonfarm Payrolls Flat in Nov.
- Unemployment Rate Drops to 4.6%
- Bond yields slip on U.S. jobs data, euro steady before Italy vote
- Alibaba (BABA) Founder Jack Ma Discuss Plans to Retire; 'I Don't Want to Die at the Office'
- Starbucks Coffee (SBUX) CEO Howard Schultz to Step Down, Appointed Executive Chairman; Kevin Johnson New CEO
Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.
Mizuho Securities reiterated a Neutral rating and $23.00 price target on Sabra Health Care REIT (NASDAQ: SBRA) after spending time with management. Mizuho said that the company comes off as much larger and influential in comparison to its relatively small size and believes that feeling comes from the operational mentality of senior management.
Analyst Richard Anderson commented, "We spent two days last week with SBRA senior management which provided insight into the company’s portfolio and strategy, as well as the post-acute and senior housing sectors in general -- the former dealing with CMS pilot programs that could test some operators' ability to remain profitable. Despite the positive impression we took away from the meetings, and there were many including management operating acumen, apparent progress on the GEN asset sales and a strong balance sheet, we remain Neutral on SBRA given the various elements of uncertainty related to execution and headline risk."
Shares of Sabra Healthcare REIT Inc. closed at $23.07 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Oppenheimer Cuts Price Target on Workday (WDAY) Following 3Q; Reiterates Outperform
- Shopify (SHOP): CFO Meetings Indicate Strong Growth Ahead - Wedbush
- Jefferies Cuts Price Target on Kroger (KR) to $30 Following 3Q and Guidance
Create E-mail Alert Related CategoriesAnalyst Comments
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!